Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC

NCT04849273 is registered in ClinicalTrials.gov with Turning Point Therapeutics, Inc. as lead sponsor.

NCT NCT04849273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04849273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC
Lead sponsor
Turning Point Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
July 28, 2021
Completion date
April 18, 2023
Enrollment
11 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, alk gene mutation, metastatic solid tumor, non small cell lung cancer, non-small cell lung cancer, nsclc